Inogen (INGN)
(Real Time Quote from BATS)
$7.01 USD
+0.23 (3.39%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $7.01 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.01 USD
+0.23 (3.39%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $7.01 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
by Zacks Equity Research
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -75.38% and 2.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Inogen (INGN) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Inogen (INGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Inogen (INGN) Surges 12.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inogen (INGN) Soars 15.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Inogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.
IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 1.22% and 1.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Inogen (INGN) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Inogen (INGN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Inogen (INGN) Loses -24.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.
Here's What Key Metrics Tell Us About Inogen (INGN) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 34.38% and 10.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 44.44% and 2.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.
Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.
Inogen (INGN) Q1 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.